

Washington University School of Medicine Digital Commons@Becker

Open Access Publications

2016

Drug delivery approaches for the treatment of cervical cancer

Farideh Ordikhani

Washington University School of Medicine in St. Louis

Mustafa Erdem Arslan

Washington University School of Medicine in St. Louis

Raymundo Marcelo

Washington University School of Medicine in St. Louis

Ilyas Sahin

Harvard University

Perry Grigsby

Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Ordikhani, Farideh; Arslan, Mustafa Erdem; Marcelo, Raymundo; Sahin, Ilyas; Grigsby, Perry; Schwarz, Julie K.; and Azab, Abdel Kareem, "Drug delivery approaches for the treatment of cervical cancer." *Pharmaceutics*.8,3. 23. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5615

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Farideh Ordikhani, Mustafa Erdem Arslan, Raymundo Marcelo, Ilyas Sahin, Perry Grigsby, Julie K. Schwarz, and Abdel Kareem Azab

Review

Drug Delivery Approaches for the Treatment of Cervical Cancer

Farideh Ordikhani ¹, Mustafa Erdem Arslan ¹, Raymundo Marcelo ¹, Ilyas Sahin ², Perry Grigsby ^{3,4}, Julie K. Schwarz ^{1,4,5} and Abdel Kareem Azab ^{1,4,*}

¹ Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, Saint Louis, MO 63108, USA; Faride.ordikhani@gmail.com (F.O.); marslan@radonc.wustl.edu (M.E.A.); raymundo.marcelo@wustl.edu (R.M.); jschwarz@radonc.wustl.edu (J.K.S.); aazab@radonc.wustl.edu (A.K.A.)

² Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA 02138, USA; ilyassahin@gmail.com

³ Department of Radiation Oncology, Radiology and Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, MO 63108, USA; pgrigsby@radonc.wustl.edu

⁴ Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO 63108, USA

⁵ Department of Radiation Oncology, Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, MO 63108, USA

* Correspondence: aazab@radonc.wustl.edu; Tel.: +1-314-362-9254

Academic Editor: Yvonne Perrie

Received: 14 June 2016; Accepted: 13 July 2016; Published: 20 July 2016

Abstract: Cervical cancer is a highly prevalent cancer that affects women around the world. With the availability of new technologies, researchers have increased their efforts to develop new drug delivery systems in cervical cancer chemotherapy. In this review, we summarized some of the recent research in systematic and localized drug delivery systems and compared the advantages and disadvantages of these methods.

Keywords: cervical cancer; drug delivery systems; systemic delivery; local delivery; chemotherapy

1. Introduction

Cervical cancer is the third most common malignancy among women, with approximately half a million newly diagnosed cases and over 200,000 deaths annually [1,2]. Although most cases of cervical cancer can be prevented by routine screening and treatment of precancerous lesions, cervical cancer is the leading cause of cancer mortality among women in developing countries [3]. Its high number of deaths is attributable to the extremely low survival rates of patients with advanced cervical cancer at diagnosis [2].

The treatment of cervical cancer is stage-specific. While early stage disease can be cured with radiotherapy or surgery, the most effective treatment for locally advanced stage patients is concurrent chemotherapy and pelvic irradiation [4,5]. Typically, once weekly cisplatin is administered intravenously while a combination of external beam radiation and brachytherapy is used to treat the pelvic tumor. Recent findings from large scale genomic sequencing of human cervical tumors has suggested that targeted therapies may present a better option [6]. Of note, it was recently shown that addition of angiogenesis inhibitor, bevacizumab, to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival [7].

Despite advances in treatment, patients with metastatic cancers and those with recurrent or persistent disease have limited treatment options [8]. A number of chemotherapeutic agents have shown activity in advanced and metastatic cervical cancer, including cisplatin [9], carboplatin [10], paclitaxel [11], ifosfamide [12], and topotecan [13]. The chemical structures of these drugs are

shown in Figure 1. Among these chemotherapeutic agents, cisplatin is considered the most effective chemotherapeutic drug for advanced cervical cancer [4]. Its efficacy is due to its induction of oxidative stress and apoptosis in tumor cells through its direct interaction with DNA forming adducts, which inhibit gene transcription [14]. However, its clinical use is limited due to tumor resistance and serious side effects like thrombocytopenia, neutropenia, nephrotoxicity, neurotoxicity, anemia due to hematological toxicity, and bone marrow depression [15,16].




Figure 1. The chemical structures of commonly used chemotherapeutic drugs in cervical cancer.

Drug delivery approaches can be categorized based on their route of administration (systemic or localized) and the type of device. Systemic delivery is based on particles (dendrimer, micelle, liposome, nano/microparticle) with surface features that help target the desired site when injected. In contrast, localized delivery limits systemic drug toxicities by direct delivery of the drug to the tumor. Based on depot systems that are implanted either directly into or adjacent to the tumor, the later promotes the release of drug directly to the cancer site [17,18]. In recent years, numerous studies have been done with localized drug delivery strategies to treat cervical cancer. Although these strategies could reduce systemic toxicity, significant improvement in delivery strategies is still necessary to increase patient compliance and reduce chemotherapy-related side effects. Fortunately, the easily-accessible cervix permits non-invasive implantation directly into the cancerous tissue at the time of brachytherapy implant [19].

In this review, we discuss the literature supporting novel drug delivery strategies for cervical cancer treatment and highlight some of the current advancements in systemic and local drug delivery systems.

2. Systemic Drug Delivery Systems

The entrapment of chemotherapeutic drug in nanocarriers has attracted considerable attention due to their structure, varied composition, and surface modifications [20]. The most common architectures for targeted drug delivery applications are nanoparticles, liposomes, micelles, and dendrimers (Figure 2). The size of these particles usually ranges from 10 to 150 nm, which ensures increased accumulation in the tumor with longer circulation time. Particle sizes of less than 10 nm would be rapidly cleared by the kidneys, and sizes larger than 150 nm would risk recognition and elimination by the macrophage cells [20]. Encapsulating chemotherapies in nanocarriers offers a number of advantages, such as protection from degradation in the bloodstream, enhancement of drug stability, targeted drug delivery, decreased toxic side effects, and improved bioavailability of the drug [21,22]. Nanoscale drug delivery systems have been shown to enhance drug specificity, decrease systemic drug toxicity, improve absorption rates, and provide protection for active agents

from biological and chemical degradation [23,24]. Moreover, they can be designed as controlled and/or sustained drug release systems to deliver therapeutics at a predetermined rate, for a specified period of time. Controlled drug delivery systems could increase patient compliance by reducing the need for repeated drug administration [25]. Little is known about the effective concentrations of drugs used with the cervix tissue, however, it is suggested that controlled released formulations with longer release will increase the local concentration of the drugs and increase efficacy of the chemotherapies.




Figure 2. Systemic Drug Delivery systems used in cervical cancer, including metal nanoparticles, polymer nanoparticles, liposomes, micelles, Antibody–Drug Conjugates (ADCs), Self-Emulsifying Drug Delivery Systems (SEDDSs) and dendrimers.

Human cancer cell lines are fundamental models, either *in vitro* as monolayer culture or *in vivo* as xenografts in mice, to study the efficacy of therapeutic agents in cancer therapy. HeLa was the first cultured cancer cell line, which was derived from cervical cancer cells taken from Henrietta Lacks in 1951 [26]. Since then, several cervical cancer cell lines including SiHa, CaSki, C-33A, and ME-180 were established [27]. It is worth to mention that these cell lines do not have equal value as tumor models, thus the *in vitro* results of drug efficacy experiments are different. On the other hand, cancer cell lines in three-dimensional (3D) culture models indicate higher malignancy, invasive characteristic, and drug resistance than classic two-dimensional (2D) cell culture [28]. Thus, limited success at translating new drug delivery systems to the clinics could be related to limitations of classic 2D cell culture and drug screening models [29].

2.1. Inorganic Nanocarriers

Nanoparticles (NPs) of noble metals have proven their efficacy in the clinical field for cancer therapy due to their unique features such as ease of synthesis, simple surface chemistry and functionalization, broad optical properties, and high surface-to-volume ratio [30]. Noble metal NPs are versatile agents with a variety of biomedical applications, including bionanomedicine [31], imaging [32], photothermal therapy [33], radiotherapy enhancement [34], and gene and drug delivery [35,36]. Recently, the antitumor potency of NPs against some cell lines has been reported [37–39]. Their effectiveness comes from their interaction with cells, where cellular uptake leads to oxidative stress from the generation of reactive oxygen species, as well as their interaction with intracellular macromolecules like DNA and proteins, since NPs can easily traverse the nuclear membrane and directly or indirectly interact with DNA, though by a still unknown mechanism [37].

Noble metal NPs are mostly made by physical and chemical methods; however, this expensive synthesis can allow toxic substances to be absorbed onto their surfaces [40]. This problem is overcome by alternative biological synthesis. The green synthesis of NPs is safe, cost-effective, and eco-friendly [41], without needing elaborate processes like multiple purification steps and microbial culture maintenance [37].

One of the most promising biomaterials in the field of nanomedicine is silver nanoparticles (AgNPs) [40,42]; its antitumor potency against cervical cancer cell lines has been recently explored. Biogenic AgNPs decreased cell proliferation and increased DNA damage, intracellular reactive oxygen species, and apoptosis, leading to cancer cell death [41]. Other studies demonstrated that particle size, dose, and time influence their toxicity [37], and that, against HeLa cervical cancer cells, AgNPs loaded with *Moringa olifera* extract showed anticancer activity [43].

Unfortunately, silver was shown to be reactive with body tissues, therefore, as a strategy to reduce the high reactivity and adverse effects of silver, AgNPs were encapsulated in gelatin or polyethylene glycol to increase the biocompatibility of the surface. However, these coated particles were less effective than the non-coated ones [44]. In another experiment, silver-core and protein-lipid-shell NPs exhibited anti-proliferative activity against HeLa cells due to enhanced cell penetration and targeted action [45].

Gold (Au) NPs emerged as a promising scaffold for chemotherapeutic drug and gene delivery vehicle, due to its high bioavailability and low immunogenicity [46]. AuNPs loaded with *Podophyllum hexandrum* exhibited an effective in vitro anti-proliferative activity against HeLa cells by induction of DNA damage and cell cycle arrest at G2/M. Further results demonstrated that the mitochondria of AuNPs-treated cells became dysfunctional due to the activation of the caspase cascade, leading to apoptosis [47]. When conjugated to gallic acid, AuNPs exhibited cytotoxicity in both Human Papilloma Virus (HPV) negative C33A cervical cancer cells and HPV type 16-positive (CaSki) or HPV type 18-positive (HeLa) cervical cancer cells, but not in normal cells in vitro [48]. Moreover, Au NPs loaded with doxorubicin exhibited stronger anticancer activity on human cervical cancer cell lines compared to free drug [49].

To improve the selective delivery of therapeutic agents to specific cells or tissues, targeting ligands (i.e., antibodies [50], aptamers [51], peptides [52,53], or small molecules [54]) are attached to the surface of the nanocarriers; which allows preferential accumulation of the nanocarriers in specific cells or tissues [55,56]. Au NPs derivatized with retinoic acid showed to improve the drug potency and cell growth inhibition up to 6 times compared to non-targeted Au NPs [57].

Other examples of biomaterials are tea polyphenol-functionalized platinum NPs (TPP@Pt), which inhibited the proliferation of and induced chromatin condensation and nuclear fragmentation of SiHa cells [58], and copper(II) complex (LQM402), which exhibited a cytotoxic effect against cell lines and selectivity for HeLa and CaSki cells, while displaying less cytotoxicity against normal fibroblasts [59].

2.2. Polymeric Nanoparticles

Biodegradable polymeric NPs have received considerable research interest in anticancer drug delivery due to their high drug loading capacity, self-stability, high cellular uptake, more desirable biodistribution, and capability to deliver both hydrophilic and hydrophobic drugs [60,61]. While the stealth polymers surrounding these NPs prolong circulation time, their dense layer of polymers could inhibit the ability of target cancer cells to uptake anticancer drugs [24].

Biodegradable polymers, either natural or synthetic, can break down through chemical or enzyme-catalyzed degradation. Biodegradable polymers offer numerous advantages in the field of drug delivery: (1) The drug release kinetics can be controlled by degradation rate of polymers, so a sustained and controlled drug release is possible; (2) the polymeric carrier would degrade into nontoxic, absorbable subunits that can be metabolized; and (3) there is no need for a follow-up surgical removal once the drug supply is depleted [62].

Nanoparticles of various polymers have been tested. One example made of different derivatives of poly(lactide-co-glycolide) (PLGA) showed sustained and controlled delivery of docetaxel for cervical cancer treatment both in vitro and in vivo and demonstrated higher cellular uptake efficiency and high antitumor efficacy [23,61,63–65]. Similarly, the acrylic polymers Eudragit-E and polyvinyl alcohol (PVA) loaded with Naringenin induced changes in mitochondrial membrane potential, augmented reactive oxygen species levels, decreased intracellular glutathione levels, produced morphological alterations in apoptosis, and caused dose-dependent cytotoxicity [66]. In another study, genistein-encapsulated ϵ -caprolactone-based NPs exhibited more cytotoxicity and tumor cell growth inhibition compared with pristine genistein in the subcutaneous HeLa xenograft tumor model in BALB/c nude mice [67].

A potential therapeutic target in cervical cancer is the folate receptor given its overexpression in human cervical cancer cells [60,68]. NPs that were conjugated with folic acid to L-tyrosine-polyphosphate [69], gelatin [60], chitosan [70], or chitosan-coated PLGA nanoparticles [71] and loaded with silver carbene complex, cisplatin, selenocystine, or carboplatin, respectively, increased the specificity of chemotherapeutic drugs up to 10-fold greater than control NPs without drug in cervical cancer cells. In vivo antitumor activity results of folate-targeted doxorubicin-loaded NPs exhibited improved targeting and anti-tumor efficacy in inhibiting tumor cells [68]. In a recent study, pullulan acetate NPs decorated with folate were used as a carrier for treating cervical carcinoma and its metastatic hepatocellular carcinoma [72].

2.3. Micelles

Made up of amphiphilic block copolymers, polymeric micelles are colloidal particles that can assemble themselves [73]. They are important for cancer therapeutic applications due to their in vivo stability, ability to solubilize water-insoluble drugs, prolongation of blood circulation time, and small size of 10 to 100 nm [74,75]. For example, polymeric composite micelles, which were targeted with folic acid and loaded with paclitaxel, inhibited tumor growth and caused cell apoptosis of U14 cervical cancer tumors both in vitro and in vivo [76].

Polymeric micelle of candesartan-g-polyethyleneimine-*cis*-1,2-cyclohexanedicarboxylic anhydride polymer loaded with paclitaxel has negative surface charges and a diameter of about 100 nm; showed strong antitumor efficacy by mediating amidase-responsive drug-release manners and quick endosomal escape [77].

2.4. Liposomes

One of the most studied nano-carriers is liposomes [78], which are single lipid bilayer vesicles that encapsulate water-soluble drugs in an aqueous core while the lipid bilayer entangles lipid-soluble drugs [74].

Liposomes were used to deliver anticancer agents including bleomycin sulfate [79], cisplatin [80], and curcumin to treat cervical cancer and could enhance bioavailability, stability, and cancerous cellular uptake of encapsulated chemotherapeutic agents [81].

Liposomal cisplatin exhibited potent antitumor activity on ME-180, R-ME-180 (ME-180 cisplatin-resistant clone), and HeLa cells. Compared to free cisplatin, liposomal cisplatin actively inhibited cell proliferation and decreased the spheroid-forming ability of R-ME-180 cells in tumors and in nude mice, in a dose-dependent manner [80].

Transferrin-targeted liposomes were shown to be more specific in delivery of paclitaxel to cervical cancer cell lines, compared to non-targeted liposomes [82]. Moreover, in vitro studies in human cervical carcinoma cell line (HeLa) showed liposomes targeted with folic acid and transferrin had higher cell association, penetration and efficacy of delivering doxorubicin compared to either of the single-ligand targeted liposomes, or non-targeted liposomes [83].

2.5. Dendrimers

Dendrimers are spherical, highly symmetric, and greatly branched, macromolecules with a well-defined structure, surface charge, and molecular size that display a high degree of monodispersity [84,85]. Their structure permits the attachment and presentation of antigen molecules at their periphery, causing them to be exceedingly multifunctional. Drugs can be loaded into cavities in their cores by chemical linkages, hydrophobic interactions, hydrogen bonds, or conjugation to the polymer scaffold [86]. For example, they can be used to overcome the poor immunogenicity of peptide-based vaccines against cervical cancer as shown by a study that developed a polyacrylate star-polymer conjugated to HPV E7 protein. It was shown that these conjugates alone and after a single immunization were able to diminish tumor growth and eliminate E7-expressing TC-1 tumors in mice [87].

Doxorubicin loaded dendrimer was conjugated with two of cancer cell targeting moieties, IL-6 antibody and RGD (Arginyl-glycyl-aspartic acid) peptide and the drug loading capacity and release profile as well as their targeting efficiency were compared. Drug loaded dendrimers decorated with IL-6 antibody exhibited higher cellular internalization, lower IC₅₀ value, higher drug loading, faster drug release rate and more cytotoxicity compared to RGD-conjugated one in HeLa cells. This could be probably because of the higher multivalent ligand density on the surface of the IL6-conjugated dendrimers, which cause better drug delivery through receptor-mediated endocytosis [88].

2.6. Self-Emulsifying Drug Delivery Systems

Another approach to improve the delivery of highly lipophilic drugs is by self-emulsifying drug delivery systems (SEDDS) [89]. SEDDS are complex formulations consisting of oil, surfactant, co-surfactant, cosolvent, and drug; upon contact with aqueous medium these isotropic preconcentrates spontaneously generate coarse emulsions, or fine nano-emulsions, referred to as self-nanoemulsifying drug delivery systems (SNEDDS) [90]. SEDDS offers numerous advantages including quick onset of action, enhancing bioavailability, minimizing side effect, control of delivery profiles, ease of manufacturing, and protection of sensitive therapeutics such as peptides, which are prone to enzymatic hydrolysis [91–93]. A few studies have shown the application of SEDDS in cervical cancer treatment; SEDDS containing antitumor agents (bleomycin, cisplatin and ifosfamide) exhibited an increase in the inhibitory effect of the drugs in a concentration-dependent manner on Hela cells [94]. In another study, SEDDS formulation was used to enhance water-solubility and bioavailability of curcumin. Oral bioavailability studies in male Wistar rats exhibited 26-fold more absorption of curcumin via its delivery through SEDDS [95].

2.7. Antibody–Drug Conjugates

Targeted delivery of drugs by conjugating them to monoclonal antibodies, which can bind specifically to tumor-associated target antigens is an innovative approach in cancer treatment that gains considerable research interest. Antibody–drug conjugates (ADCs) can selectively deliver therapeutics to tumor cells and provide sustained clinical benefit to cancer patients with less systemic toxicity [96]. Furthermore, ADCs allow more delivery of the drug over repeated cycles of therapy, and consequently improving the therapeutic index, or ratio of efficacy to toxicity of the drug [97]. Although ADCs approaches are promising, a few of them are approved for clinical use such as Brentuximab vedotin (Adcetris®) and ado-trastuzumab emtansine (Kadcyla®) [98,99]. Insufficient understanding of ADCs mechanism of action, inadequate knowledge of the management and understanding of ADCs off-target toxicities, and difficulties in the selection of suitable clinical settings such as patient selection, dosing regimen are some possible explanations for the slow clinical translation of new ADCs [97]. TF-011-MMAE (HuMax-TF-ADC), an antibody drug conjugate targeting tissue factor-specific cells, exhibited excellent antitumor activity in patients with advanced solid cancers, including cervical

cancer [100]. Another new clinical trial of ADCs is IMMU-132, which is targeting the TROP-2 antigen and expressed by many human solid tumors including breast, colon and rectum, lung, pancreas, ovary, prostate, and cervical cancers [101,102].

3. Localized Drug Delivery Systems

Localized delivery of chemotherapeutic drugs to the cervix offers a number of advantages compared to systemic delivery such as its avoidance of systemic chemotherapeutic drug circulation, which leads to less drug waste and decreased side effects and delivery of high dose of the active agent in the cervix which improves the efficacy of the treatment [18] (Figure 3). The use of local drug delivery systems for the treatment of metastatic cervical tumors may be inefficient, where the disease is disseminated in distant organs, which implies the need of a more systemic approach. However, recent reports show that less than 20% of the cases appear with distant metastasis [103], which emphasizes that most of the cervical cancer cases would benefit from localized drug delivery systems.




Figure 3. Drug Localized Drug Delivery systems used in cervical cancer, including vaginal rings, vaginal films, cervical patches, nanofibers, gels and CerviPrep™.

This direct delivery is possible due to the easily reachable location of the cervix through the vagina [104]. Presently, different drugs in various forms such as gels, rings, fibers, and tablets are delivered through the vagina for purposes such as contraception or the treatment of fungal, bacterial, and sexually transmitted infections [105–107]. Many of these methods have already been studied for use in chemotherapeutic localized delivery, and, with such a wide range of formulations, patient treatment can be individualized by type and dosing of the drug regimen. Improving the overall quality of patients' lives, localized delivery helps patients recover more quickly and reduces the number of hospital presentations and admissions, decreasing global healthcare system costs [19].

3.1. Intra-Vaginal Rings

As flexible and torus-shaped delivery systems, intra-vaginal rings can provide both sustained and controlled drug release, lasting for several weeks to several months [108]. Recently, intra-vaginal rings have been used for the localized delivery of a chemotherapeutic drug to the cervix with the potential to reduce the need for surgical intervention. Poly(ethylene-co-vinyl acetate) ring device incorporated with cisplatin for local treatment of cervical cancer were recently reported. The intra-vaginal rings were found to be effective against both HPV positive and HPV negative cervical cancer cells in vitro [104].

Other thermoplastic vaginal rings were shown to hold and release disulfiram, an anticancer drug, at levels far beyond the IC_{50} value for HeLa cells [108].

3.2. Nanofibers

Nanofibers have various applications, one of which is drug delivery, especially in local chemotherapy. Their attractive characteristics for electrospinning used in drug delivery are high encapsulation efficiency, ease of operation, cost-effectiveness, high loading capacity, and simultaneous delivery of various therapies [109]. Recently, drug-loaded ultrafine fibers have been used in local chemotherapy of cervical cancers. Biodegradable polylactide fiber mats loaded with paclitaxel showed strong inhibition of xenograft U14 cervical cancer [110]. At the same drug level, the *in vivo* trials of cisplatin-loaded biodegradable poly(ethylene oxide)/polylactide composite electrospun nanofibers demonstrated more antitumor efficacy with better systemic safety than the IV injection group [2], indicating the benefits of localized delivery over systematic delivery.

3.3. Vaginal Films

Vaginal films made are promising delivery systems that could achieve better patient compliance and therapeutic efficacy. Curcumin-hydroxypropyl cyclodextrin complex vaginal films were shown to be retained in the vaginal mucosa for up to six hours, making it a potentially effective therapy for HPV-induced cervical cancer [111].

3.4. Gels

As proven and accepted therapeutics, vaginally-applied gels have drugs and active ingredients which can restore physiological pH, moisturize and lubricate, be a contraceptive or labor inducer, and/or have microbicide activity [106]. In regards to treatment of HPV-induced cervical cancer, a vaginal gel using the biodegradable thermosensitive polymer Pluronic® F127 combined with 5-fluorouracil and alternative mucoadhesive polymers like Carbopol 934, hydroxypropylmethylcellulose, and hyaluronic acid was created. Cytotoxicity studies with HeLa cells showed that complexes of 1% 5-fluorouracil and β -cyclodextrin or hydroxypropyl- β -cyclodextrin were just as effective as free 5-fluorouracil. These results indicate that a lower dose of this anticancer drug can achieve better therapeutic efficacy and increased patient compliance [112]. Although gels are tolerated more than other dosage forms, they can easily leak out of the vagina [2].

3.5. Cervical Patches

Another approach to the cervical delivery of a cytotoxic agent is using bioadhesive cervical patches [113]. In one study, a patch containing 20 mg of 5-fluorouracil was paired with cervical tissue samples for a 24-hour period. After this exposure, the tissue concentration of 5-fluorouracil was found to be 100 times that of the determined cytotoxic drug concentration. This outcome shows that for areas of the cervical stroma where pre-cancerous lesions can occur, the patch delivery system could provide clinically effective drug concentrations [114]. However, the turnover of the mucosal lining limits these patches [104].

3.6. CerviPrep™

Hodge et al. developed a new cervical delivery instrument (CerviPrep™) that consisted of a tubular applicator with a cervical cap on one end. When the cervical cap was positioned over the patient's cervix, this device could directly apply pharmaceuticals to the cervix with limited exposure to and absorption by the adjacent vaginal tissue. The results of clinical studies with the CerviPrep™ delivery device showed limited systemic exposure and no toxicities [115].

4. Conclusion and Future Direction

Inorganic, lipidic and polymeric nanocarriers are promising candidates for the development of systemic delivery systems in cervical cancer chemotherapy. Experimental results show great potential for the widespread adoption of nanocarriers in cervical cancer treatment over conventional chemotherapy. Their attractive properties include biocompatibility, low toxicity, lower clearance rates, the ability to target specific tissues, and controlled release of chemotherapeutic agents. However, the toxicology of nanocarriers in humans still needs to be fully studied. On the other hand, localized delivery of chemotherapeutic drugs to the cervix offers a number of advantages such as increased efficacy and decreased side effects due to direct delivery to the site of cancer, which avoids systemic circulation of chemotherapeutic drugs. However, the local drug delivery systems are not effective in metastatic tumors. The therapeutic use of these drug delivery devices and formulations would vary depending on the patient's cancer stage. Any vaginal drug delivery device or formulations could be used to provide local delivery of a chemotherapeutic drug to the cervix, and each has its own advantages like improved patient compliance and disadvantages like expensive production. Although, localized delivery of chemotherapeutic drugs directly to the cervix will improve the patient's overall quality of life and reduce hospital presentations and cost, more research needs to be performed characterizing the local accumulation and efficacy of drugs in the cervix.

Acknowledgments: Abdel Kareem Azab is supported by grants from National Institutes of Health under Award Number U54CA199092, the Multiple Myeloma Research Foundation, and the International Waldenstrom Macroglobulinemia Foundation. Julie K. Schwarz is supported by National Institutes of Health under Award Number R01CA181745-01.

Conflicts of Interest: Abdel Kareem Azab reports receiving commercial research grant from Selexys, Verastem, Karyopharm, Cellworks, Cleave, Glycomimetics, and Vasculox; and is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC. Moreover, Abdel Kareem Azab and Julie K. Schwarz have a pending provisional patent application describing a novel localized drug delivery system for cervical cancer. No potential conflicts of interest were disclosed by the other authors.

References

1. Shazly, S.A.M.; Murad, M.H.; Dowdy, S.C.; Gostout, B.S.; Famuyide, A.O. Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis. *Gynecol. Oncol.* **2015**, *138*, 457–471. [[CrossRef](#)] [[PubMed](#)]
2. Zong, S.; Wang, X.; Yang, Y.; Wu, W.; Li, H.; Ma, Y.; Lin, W.; Sun, T.; Huang, Y.; Xie, Z.; et al. The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. *Eur. J. Pharm. Biopharm.* **2015**, *93*, 127–135. [[CrossRef](#)] [[PubMed](#)]
3. Aggarwal, P. Cervical cancer: Can it be prevented? *World. J. Clin. Oncol.* **2014**, *5*, 775–780. [[CrossRef](#)] [[PubMed](#)]
4. Lorusso, D.; Petrelli, F.; Coinu, A.; Raspagliesi, F.; Barni, S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. *Gynecol. Oncol.* **2014**, *133*, 117–123. [[CrossRef](#)] [[PubMed](#)]
5. Kang, Y.-J.; O'Connell, D.L.; Tan, J.; Lew, J.-B.; Demers, A.; Lotocki, R.; Kliewer, E.V.; Hacker, N.F.; Jackson, M.; Delaney, G.P.; et al. Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in australia and canada: Results from two large cancer facilities. *Cancer. Epidemiol.* **2015**, *39*, 600–611. [[CrossRef](#)] [[PubMed](#)]
6. Ojesina, A.I.; Lichtenstein, L.; Freeman, S.S.; Pedamallu, C.S.; Imaz-Rosshandler, I.; Pugh, T.J.; Cherniack, A.D.; Ambrogio, L.; Cibulskis, K.; Bertelsen, B.; et al. Landscape of genomic alterations in cervical carcinomas. *Nature* **2014**, *506*, 371–375. [[CrossRef](#)] [[PubMed](#)]
7. Tewari, K.S.; Sill, M.W.; Long, H.J.; Penson, R.T.; Huang, H.; Ramondetta, L.M.; Landrum, L.M.; Oaknin, A.; Reid, T.J.; Leitao, M.M.; et al. Improved survival with bevacizumab in advanced cervical cancer. *New Engl. J. Med.* **2014**, *370*, 734–743. [[CrossRef](#)] [[PubMed](#)]
8. Pfendler, K.S.; Tewari, K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. *Am. J. Obstet. Gynecol.* **2016**, *214*, 22–30. [[CrossRef](#)] [[PubMed](#)]

9. Leisching, G.R.; Loos, B.; Botha, M.H.; Engelbrecht, A.M. The role of mtor during cisplatin treatment in an in vitro and ex vivo model of cervical cancer. *Toxicol.* **2015**, *335*, 72–78. [[CrossRef](#)] [[PubMed](#)]
10. Katanyoo, K.; Tangjitgamol, S.; Chongthanakorn, M.; Tantivatana, T.; Manusirivithaya, S.; Rongsriyam, K.; Cholpaisal, A. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. *Gynecol. Oncol.* **2011**, *123*, 571–576. [[CrossRef](#)] [[PubMed](#)]
11. Wang, X.; Shen, Y.; Zhao, Y.; Li, Z.; Gou, H.; Cao, D.; Yang, Y.; Qiu, M.; Li, Q.; Liu, J.; et al. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase ii trial. *Eur. J. Surg. Oncol. (EJSO)* **2015**, *41*, 1082–1088. [[CrossRef](#)] [[PubMed](#)]
12. Downs, L.S., Jr.; Chura, J.C.; Argenta, P.A.; Judson, P.L.; Ghebre, R.; Geller, M.A.; Carson, L.F. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase ii trial. *Gynecol. Oncol.* **2011**, *120*, 265–269. [[CrossRef](#)] [[PubMed](#)]
13. Muderspach, L.I.; Blessing, J.A.; Levenback, C.; Moore, J.L., Jr. A phase ii study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study. *Gynecol. Oncol.* **2001**, *81*, 213–215. [[CrossRef](#)] [[PubMed](#)]
14. Oz, M.; Nurullahoglu Atalik, K.E.; Yerlikaya, F.H.; Demir, E.A. Curcumin alleviates cisplatin-induced learning and memory impairments. *Neurobiol. Learn. Mem.* **2015**, *123*, 43–49. [[CrossRef](#)] [[PubMed](#)]
15. De Freitas, L.M.; Soares, C.P.; Fontana, C.R. Synergistic effect of photodynamic therapy and cisplatin: A novel approach for cervical cancer. *J. Photochem. Photobiol. B* **2014**, *140*, 365–373. [[CrossRef](#)] [[PubMed](#)]
16. Das, R.; Bhattacharya, K.; Samanta, S.K.; Pal, B.C.; Mandal, C. Improved chemosensitivity in cervical cancer to cisplatin: Synergistic activity of mahanine through STAT3 inhibition. *Cancer Lett.* **2014**, *351*, 81–90. [[CrossRef](#)] [[PubMed](#)]
17. Yohe, S.T.; Herrera, V.L.M.; Colson, Y.L.; Grinstaff, M.W. 3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells. *J. Control. Release* **2012**, *162*, 92–101. [[CrossRef](#)] [[PubMed](#)]
18. Wolinsky, J.B.; Colson, Y.L.; Grinstaff, M.W. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers. *J. Control. Release* **2012**, *159*, 14–26. [[CrossRef](#)] [[PubMed](#)]
19. McConville, C. The use of localised vaginal drug delivery as part of a neoadjuvant chemotherapy strategy in the treatment of cervical cancer. *Gynecol. Obstet. Res. Open. J.* **2015**, *2*, 26–28. [[CrossRef](#)]
20. Kijanka, M.; Dorresteijn, B.; Oliveira, S.; en Henegouwen, P.M.V.B. Nanobody-based cancer therapy of solid tumors. *Nanomedicine* **2015**, *10*, 161–174. [[CrossRef](#)] [[PubMed](#)]
21. Ye, H.; Karim, A.A.; Loh, X.J. Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review. *Mater. Sci. Eng.* **2014**, *45*, 609–619. [[CrossRef](#)] [[PubMed](#)]
22. Parveen, S.; Misra, R.; Sahoo, S.K. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine* **2012**, *8*, 147–166. [[CrossRef](#)] [[PubMed](#)]
23. Ma, Y.; Huang, L.; Song, C.; Zeng, X.; Liu, G.; Mei, L. Nanoparticle formulation of poly(ϵ -caprolactone-co-lactide)-*d*- α -tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. *Polymer* **2010**, *51*, 5952–5959. [[CrossRef](#)]
24. Sun, L.; Wu, Q.; Peng, F.; Liu, L.; Gong, C. Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy. *Colloids Surf. B* **2015**, *135*, 56–72. [[CrossRef](#)] [[PubMed](#)]
25. Siegel, R.A.; Rathbone, M.J. Overview of controlled release mechanisms. In *Fundamentals and Applications of Controlled Release Drug Delivery*; Siepmann, J., Siegel, A.R., Rathbone, J.M., Eds.; Springer US: Boston, MA, USA, 2012; pp. 19–43.
26. Lucey, B.P.; Nelson-Rees, W.A.; Hutchins, G.M. Henrietta lacks, hela cells, and cell culture contamination. *Archiv. Pathol. Lab. Med.* **2009**, *133*, 1463–1467.
27. Gillet, J.-P.; Varma, S.; Gottesman, M.M. The clinical relevance of cancer cell lines. *JNCI J. Nat. Cancer Inst.* **2013**, *105*, 452–458. [[CrossRef](#)] [[PubMed](#)]
28. Ordikhani, F.; Kim, Y.; Zustiak, S.P. The role of biomaterials on cancer stem cell enrichment and behavior. *JOM* **2015**, *67*, 2543–2549. [[CrossRef](#)]
29. de la Puente, P.; Muz, B.; Gilson, R.C.; Azab, F.; Luderer, M.; King, J.; Achilefu, S.; Vij, R.; Azab, A.K. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. *Biomater.* **2015**, *73*, 70–84. [[CrossRef](#)] [[PubMed](#)]
30. Conde, J.; Doria, G.; Baptista, P. Noble metal nanoparticles applications in cancer. *J. Drug Deliv.* **2012**, *2012*, 12. [[CrossRef](#)] [[PubMed](#)]

31. Kumar, A.; Mazinder Boruah, B.; Liang, X.-J. Gold nanoparticles: Promising nanomaterials for the diagnosis of cancer and hiv /aids. *J. Nanomater.* **2011**, *2011*, 17. [[CrossRef](#)]
32. Jain, P.K.; Huang, X.; El-Sayed, I.H.; El-Sayed, M.A. Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. *Acc. Chem. Res.* **2008**, *41*, 1578–1586. [[CrossRef](#)] [[PubMed](#)]
33. Sau, T.K.; Rogach, A.L.; Jäckel, F.; Klar, T.A.; Feldmann, J. Properties and applications of colloidal nonspherical noble metal nanoparticles. *Adv. Mater.* **2010**, *22*, 1805–1825. [[CrossRef](#)] [[PubMed](#)]
34. Lee, J.; Chatterjee, D.K.; Lee, M.H.; Krishnan, S. Gold nanoparticles in breast cancer treatment: Promise and potential pitfalls. *Cancer Lett.* **2014**, *347*, 46–53. [[CrossRef](#)] [[PubMed](#)]
35. Kumar, A.; Zhang, X.; Liang, X.-J. Gold nanoparticles: Emerging paradigm for targeted drug delivery system. *Biotechnol. Adv.* **2013**, *31*, 593–606. [[CrossRef](#)] [[PubMed](#)]
36. Pissuwan, D.; Niidome, T.; Cortie, M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. *J. Control. Release* **2011**, *149*, 65–71. [[CrossRef](#)] [[PubMed](#)]
37. Jeyaraj, M.; Sathishkumar, G.; Sivanandhan, G.; MubarakAli, D.; Rajesh, M.; Arun, R.; Kapildev, G.; Manickavasagam, M.; Thajuddin, N.; Premkumar, K.; et al. Biogenic silver nanoparticles for cancer treatment: An experimental report. *Colloids Surf. B* **2013**, *106*, 86–92. [[CrossRef](#)] [[PubMed](#)]
38. Nayak, D.; Pradhan, S.; Ashe, S.; Rauta, P.R.; Nayak, B. Biologically synthesised silver nanoparticles from three diverse family of plant extracts and their anticancer activity against epidermoid a431 carcinoma. *J. Colloid Interface Sci.* **2015**, *457*, 329–338. [[CrossRef](#)] [[PubMed](#)]
39. Mukherjee, S.; Ghosh, S.; Das, D.K.; Chakraborty, P.; Choudhury, S.; Gupta, P.; Adhikary, A.; Dey, S.; Chattopadhyay, S. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection—Synthesis, characterization and in vitro evaluation. *J. Nutr. Biochem.* **2015**, *26*, 1283–1297. [[CrossRef](#)] [[PubMed](#)]
40. Prabhu, S.; Poullose, E. Silver nanoparticles: Mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. *Int. Nano Lett.* **2012**, *2*, 1–10. [[CrossRef](#)]
41. Jeyaraj, M.; Rajesh, M.; Arun, R.; MubarakAli, D.; Sathishkumar, G.; Sivanandhan, G.; Dev, G.K.; Manickavasagam, M.; Premkumar, K.; Thajuddin, N.; et al. An investigation on the cytotoxicity and caspase-mediated apoptotic effect of biologically synthesized silver nanoparticles using podophyllum hexandrum on human cervical carcinoma cells. *Colloids Surf. B* **2013**, *102*, 708–717. [[CrossRef](#)] [[PubMed](#)]
42. Lansdown, A.B. Silver. I: Its antibacterial properties and mechanism of action. *J. Wound Care* **2002**, *11*, 125–130. [[CrossRef](#)] [[PubMed](#)]
43. Vasanth, K.; Ilango, K.; MohanKumar, R.; Agrawal, A.; Dubey, G.P. Anticancer activity of moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction. *Colloids Surf. B* **2014**, *117*, 354–359. [[CrossRef](#)] [[PubMed](#)]
44. Casañas Pimentel, R.; San Martín Martínez, E.; Monroy García, A.; Gómez-García, C.; Alvarado Palacios, Q.G. Silver nanoparticles nanocarriers, synthesis and toxic effect on cervical cancer cell lines. *BioNanoSci.* **2013**, *3*, 198–207. [[CrossRef](#)]
45. Rajasekharreddy, P.; Rani, P.U. Biofabrication of ag nanoparticles using sterculia foetida l. Seed extract and their toxic potential against mosquito vectors and HeLa cancer cells. *Mater. Sci. Eng.* **2014**, *39*, 203–212. [[CrossRef](#)] [[PubMed](#)]
46. Ghosh, P.; Han, G.; De, M.; Kim, C.K.; Rotello, V.M. Gold nanoparticles in delivery applications. *Adv. Drug Deliv. Rev.* **2008**, *60*, 1307–1315. [[CrossRef](#)] [[PubMed](#)]
47. Jeyaraj, M.; Arun, R.; Sathishkumar, G.; MubarakAli, D.; Rajesh, M.; Sivanandhan, G.; Kapildev, G.; Manickavasagam, M.; Thajuddin, N.; Ganapathi, A. An evidence on G2/M arrest, DNA damage and caspase mediated apoptotic effect of biosynthesized gold nanoparticles on human cervical carcinoma cells (HeLa). *Mater. Res. Bull.* **2014**, *52*, 15–24. [[CrossRef](#)]
48. Daduang, J.; Palasap, A.; Daduang, S.; Boonsiri, P.; Suwannalert, P.; Limpai boon, T. Gallic acid enhancement of gold nanoparticle anticancer activity in cervical cancer cells. *Asian Pac. J. Cancer Prev.* **2015**, *16*, 169–174. [[CrossRef](#)] [[PubMed](#)]
49. Tomoaia, G.; Horovitz, O.; Mocanu, A.; Nita, A.; Avram, A.; Racz, C.P.; Soritau, O.; Cenariu, M.; Tomoaia-Cotisel, M. Effects of doxorubicin mediated by gold nanoparticles and resveratrol in two human cervical tumor cell lines. *Colloids Surf. B* **2015**, *135*, 726–734. [[CrossRef](#)] [[PubMed](#)]

50. Firer, M.A.; Gellerman, G. Targeted drug delivery for cancer therapy: The other side of antibodies. *J. Hematol. Oncol.* **2012**, *5*, 70. [[CrossRef](#)] [[PubMed](#)]
51. Chen, Y.; Wang, J.; Wang, J.; Wang, L.; Tan, X.; Tu, K.; Tong, X.; Qi, L. Aptamer functionalized cisplatin-albumin nanoparticles for targeted delivery to epidermal growth factor receptor positive cervical cancer. *J. Biomed. Nanotechnol.* **2016**, *12*, 656–666. [[CrossRef](#)] [[PubMed](#)]
52. Vives, E.; Schmidt, J.; Pelegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. *Biochim. Biophys. Acta (BBA) Rev. Cancer* **2008**, *1786*, 126–138. [[CrossRef](#)] [[PubMed](#)]
53. Majumdar, S.; Siahaan, T.J. Peptide-mediated targeted drug delivery. *Med. Res. Rev.* **2012**, *32*, 637–658. [[CrossRef](#)] [[PubMed](#)]
54. Kue, C.S.; Kamkaew, A.; Burgess, K.; Kiew, L.V.; Chung, L.Y.; Lee, H.B. Small molecules for active targeting in cancer. *Med. Res. Rev.* **2016**, *36*, 494–575. [[CrossRef](#)] [[PubMed](#)]
55. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. *Drug Discov. Today* **2003**, *8*, 1112–1120. [[CrossRef](#)]
56. Sinha, R.; Kim, G.J.; Nie, S.; Shin, D.M. Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. *Mol. Cancer Ther.* **2006**, *5*, 1909–1917. [[CrossRef](#)] [[PubMed](#)]
57. Ye, L.; Song, Q. Promising potency of retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment. *Int. J. Clin. Exp. Med.* **2015**, *8*, 10501–10507. [[PubMed](#)]
58. Alshatwi, A.A.; Athinarayanan, J.; Vaiyapuri Subbarayan, P. Green synthesis of platinum nanoparticles that induce cell death and G2/M-phase cell cycle arrest in human cervical cancer cells. *J. Mater. Sci.* **2014**, *26*, 1–9. [[CrossRef](#)] [[PubMed](#)]
59. Frías González, S.E.; Angeles Anguiano, E.; Mendoza Herrera, A.; Escutia Calzada, D.; Ordaz Pichardo, C. Cytotoxic, pro-apoptotic, pro-oxidant, and non-genotoxic activities of a novel copper(ii) complex against human cervical cancer. *Toxicol.* **2013**, *314*, 155–165. [[CrossRef](#)] [[PubMed](#)]
60. Dixit, N.; Vaibhav, K.; Pandey, R.S.; Jain, U.K.; Katare, O.P.; Katyal, A.; Madan, J. Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. *Biomed. Pharmacother.* **2015**, *69*, 1–10. [[CrossRef](#)] [[PubMed](#)]
61. Zeng, X.; Tao, W.; Mei, L.; Huang, L.; Tan, C.; Feng, S.-S. Cholic acid-functionalized nanoparticles of star-shaped P-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. *Biomater.* **2013**, *34*, 6058–6067. [[CrossRef](#)] [[PubMed](#)]
62. JOSHI, J.R.; PATEL, R.P. Role of biodegradable polymers in drug delivery. *Int. J. Curr. Pharm. Res.* **2012**, *4*, 74–81.
63. Yang, H.; Li, K.; Liu, Y.; Liu, Z.; Miyoshi, H. Poly(D,L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: Preparation, release kinetics and anticancer effect. *J. Nanosci. Nanotechnol.* **2009**, *9*, 282–287. [[CrossRef](#)] [[PubMed](#)]
64. Qiu, B.; Ji, M.; Song, X.; Zhu, Y.; Wang, Z.; Zhang, X.; Wu, S.; Chen, H.; Mei, L.; Zheng, Y. Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer. *Nanoscale Res. Lett.* **2012**, *7*, 1–11. [[CrossRef](#)] [[PubMed](#)]
65. Ma, Y.; Zheng, Y.; Liu, K.; Tian, G.; Tian, Y.; Xu, L.; Yan, F.; Huang, L.; Mei, L. Nanoparticles of poly(lactide-co-glycolide)-*d*- α -tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. *Nanoscale Res. Lett.* **2010**, *5*, 1161–1169. [[CrossRef](#)] [[PubMed](#)]
66. Krishnakumar, N.; Sulfikkarali, N.; RajendraPrasad, N.; Karthikeyan, S. Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical (HeLa) cancer cells. *Biomed. Prev. Nutr.* **2011**, *1*, 223–231. [[CrossRef](#)]
67. Zhang, H.; Liu, G.; Zeng, X.; Wu, Y.; Yang, C.; Mei, L.; Wang, Z.; Huang, L. Fabrication of genistein-loaded biodegradable TPGS-*b*-PCL nanoparticles for improved therapeutic effects in cervical cancer cells. *Int. J. Nanomed.* **2015**, *10*, 2461–2473.
68. Zhang, C.; Zhang, Z.; Zhao, L. Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: Optimization and in vivo antitumor activity. *Drug Deliv.* **2016**, *23*, 1830–1837. [[CrossRef](#)] [[PubMed](#)]
69. Ditto, A.J.; Shah, K.N.; Robishaw, N.K.; Panzner, M.J.; Youngs, W.J.; Yun, Y.H. The interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flow. *Mol. Pharm.* **2012**, *9*, 3089–3098. [[CrossRef](#)] [[PubMed](#)]

70. Yu, B.; Li, H.; Zhang, J.; Zheng, W.; Chen, T. Rational design and fabrication of a cancer-targeted chitosan nanocarrier to enhance selective cellular uptake and anticancer efficacy of selenocystine. *J. Mater. Chem. B* **2015**, *3*, 2497–2504. [[CrossRef](#)]
71. Ji, J.; Zuo, P.; Wang, Y.L. Enhanced antiproliferative effect of carboplatin in cervical cancer cells utilizing folate-grafted polymeric nanoparticles. *Nanoscale Res. Lett.* **2015**. [[CrossRef](#)] [[PubMed](#)]
72. Tang, H.; Feng, X.; Zhang, T.; Dai, Y.; Zhou, Z.; Chen, H.; Liu, L.; Li, X.; Zhuang, T.; Liu, X.; et al. Stability, pharmacokinetics, biodistribution and safety assessment of folate-conjugated pullulan acetate nanoparticles as cervical cancer targeted drug carriers. *J. Nanosci. Nanotechnol.* **2015**, *15*, 6405–6412. [[CrossRef](#)] [[PubMed](#)]
73. Hu, Q.; van Gaal, E.V.B.; Brundel, P.; Ippel, H.; Hackeng, T.; Rijcken, C.J.F.; Storm, G.; Hennink, W.E.; Prakash, J. A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. *J. Control. Release* **2015**, *205*, 98–108. [[CrossRef](#)] [[PubMed](#)]
74. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. *Urol. Oncol.* **2008**, *26*, 57–64. [[CrossRef](#)] [[PubMed](#)]
75. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized micellar systems for cancer targeted drug delivery. *Pharm. Res.* **2007**, *24*, 1029–1046. [[CrossRef](#)] [[PubMed](#)]
76. Chen, F.; Dong, D.; Fu, F.; Zheng, Y.H.; Liu, S.; Chang, M.X.; Jing, X.B. Anti-tumor activity of biodegradable polymer-paclitaxel conjugated micelle against mice U14 cervical cancers. *Chem. Res. Chin. Univ.* **2012**, *28*, 656–661.
77. Guo, Q.; Guan, D.; Dong, B.; Nan, F.; Zhang, Y. Charge-conversional binary drug delivery polymeric micelles for combined chemotherapy of cervical cancer. *Int. J. Polym. Mater. Polym. Biomater.* **2015**, *64*, 978–987. [[CrossRef](#)]
78. Movahedi, F.; Hu, R.G.; Becker, D.L.; Xu, C. Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics. *Nanomedicine* **2015**, *11*, 1575–1584. [[CrossRef](#)] [[PubMed](#)]
79. Saini, J.; Bansal, V.; Chandra, A.; Madan, J.; Jain, U.K.; Chandra, R.; Jain, S.M. Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells. *Colloids Surf. B* **2014**, *118*, 101–110. [[CrossRef](#)] [[PubMed](#)]
80. Casagrande, N.; De Paoli, M.; Celegato, M.; Borghese, C.; Mongiat, M.; Colombatti, A.; Aldinucci, D. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. *Gynecol. Oncol.* **2013**, *131*, 744–752. [[CrossRef](#)] [[PubMed](#)]
81. Saengkrit, N.; Saesoo, S.; Srinuanchai, W.; Phunpee, S.; Ruktanonchai, U.R. Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. *Colloids Surf. B* **2014**, *114*, 349–356. [[CrossRef](#)] [[PubMed](#)]
82. Zhao, C.; Liu, X.; Liu, J.; Yang, Z.; Rong, X.; Li, M.; Liang, X.; Wu, Y. Transferrin conjugated poly(γ -glutamic acid-maleimide-co-L-lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticles for targeting drug delivery. *Colloids Surf. B* **2014**, *123*, 787–796. [[CrossRef](#)] [[PubMed](#)]
83. Sriraman, S.K.; Salzano, G.; Sarisozen, C.; Torchilin, V. Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. *Eur. J. Pharm. Biopharm.* **2016**, *105*, 40–49. [[CrossRef](#)] [[PubMed](#)]
84. Kesharwani, P.; Banerjee, S.; Gupta, U.; Mohd Amin, M.C.I.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Pamam dendrimers as promising nanocarriers for RNAi therapeutics. *Mater. Today* **2015**, *18*, 565–572. [[CrossRef](#)]
85. Steichen, S.D.; Caldorera-Moore, M.; Peppas, N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. *Eur. J. Pharm. Sci.* **2013**, *48*, 416–427. [[CrossRef](#)] [[PubMed](#)]
86. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. *Annu. Rev. Med.* **2012**, *63*, 185–198. [[CrossRef](#)] [[PubMed](#)]
87. Liu, T.-Y.; Hussein, W.M.; Jia, Z.; Ziora, Z.M.; McMillan, N.A.J.; Monteiro, M.J.; Toth, I.; Skwarczynski, M. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. *Biomacromol.* **2013**, *14*, 2798–2806. [[CrossRef](#)] [[PubMed](#)]
88. Mekuria, S.L.; Debele, T.A.; Chou, H.-Y.; Tsai, H.-C. IL-6 antibody and RGD peptide conjugated poly(amidoamine) dendrimer for targeted drug delivery of HeLa cells. *J. Phys. Chem. B* **2016**, *120*, 123–130. [[CrossRef](#)] [[PubMed](#)]
89. Neslihan Gursoy, R.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomed. Pharmacother.* **2004**, *58*, 173–182. [[CrossRef](#)] [[PubMed](#)]
90. Thomas, N.; Holm, R.; Rades, T.; Müllertz, A. Characterising lipid lipolysis and its implication in lipid-based formulation development. *AAPS J.* **2012**, *14*, 860–871. [[CrossRef](#)] [[PubMed](#)]

91. Ujhelyi, Z.; Vecsernyés, M.; Bácskay, I. Formulation and characterization of self-microemulsifying drug delivery systems according to their cytotoxic attributes. *Acta. Pharm. Hung.* **2014**, *84*, 69–76. [[PubMed](#)]
92. Nigade, P.M.; Patil, S.L.; Tiwari, S.S. Self emulsifying drug delivery system (SEDDS): A review. *Int. J. of Pharm. Biol. Sci.* **2012**, *2*, 42–52.
93. Kumar, A.; Sharma, S.; Kamble, R. Self emulsifying drug delivery system (SEDDS): Future aspects. *Int. J. Pharm. Pharm. Sci.* **2010**, *2*, 7–13.
94. Ujhelyi, Z.; Kalantari, A.; Vecsernyés, M.; Róka, E.; Fenyvesi, F.; Póka, R.; Kozma, B.; Bácskay, I. The enhanced inhibitory effect of different antitumor agents in self-microemulsifying drug delivery systems on human cervical cancer hela cells. *Molecules* **2015**, *20*, 13226–13239. [[CrossRef](#)] [[PubMed](#)]
95. Dhumal, D.M.; Kothari, P.R.; Kalhapure, R.S.; Akamanchi, K.G. Self-microemulsifying drug delivery system of curcumin with enhanced solubility and bioavailability using a new semi-synthetic bicephalous heterolipid: In vitro and in vivo evaluation. *RSC Adv.* **2015**, *5*, 90295–90306. [[CrossRef](#)]
96. Bouchard, H.; Viskov, C.; Garcia-Echeverria, C. Antibody–drug conjugates—A new wave of cancer drugs. *Bioorganic Med. Chem. Lett.* **2014**, *24*, 5357–5363. [[CrossRef](#)] [[PubMed](#)]
97. Sassoon, I.; Blanc, V. Antibody–drug conjugate (ADC) clinical pipeline: A review. In *Antibody-drug conjugates*; Ducry, L., Ed.; Humana Press: Totowa, NJ, USA, 2013; pp. 1–27.
98. Peters, C.; Brown, S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. *Biosci. Rep.* **2015**. [[CrossRef](#)] [[PubMed](#)]
99. Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Site-specific antibody drug conjugates for cancer therapy. *mAbs* **2014**, *6*, 34–45. [[CrossRef](#)] [[PubMed](#)]
100. Breij, E.C.W.; de Goeij, B.E.C.G.; Verploegen, S.; Schuurhuis, D.H.; Amirkhosravi, A.; Francis, J.; Miller, V.B.; Houtkamp, M.; Bleeker, W.K.; Satijn, D.; et al. An antibody–drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. *Cancer Res.* **2014**, *74*, 1214–1226. [[CrossRef](#)] [[PubMed](#)]
101. Bardia, A.; Starodub, A.; Moroosse, R.L.; Mayer, I.A.; Diamond, J.R.; Chuang, E.; Govindan, S.V.; Sharkey, R.M.; Maliakal, P.; Wegener, W.A.; et al. Abstract p5-19-27: Immu-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from phase I/II clinical trial (nct01631552). *Cancer Res.* **2015**. [[CrossRef](#)]
102. Goldenberg, D.M.; Cardillo, T.M.; Govindan, S.V.; Rossi, E.A.; Sharkey, R.M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (immu-132), an antibody-drug conjugate (ADC). *Oncotarget* **2015**, *6*, 22496–22512. [[CrossRef](#)] [[PubMed](#)]
103. Williams, N.L.; Werner, T.L.; Jarboe, E.A.; Gaffney, D.K. Adenocarcinoma of the cervix: Should we treat it differently? *Curr. Oncol. Rep.* **2015**, *17*, 1–10. [[CrossRef](#)] [[PubMed](#)]
104. Keskar, V.; Mohanty, P.S.; Gemeinhart, E.J.; Gemeinhart, R.A. Cervical cancer treatment with a locally insertable controlled release delivery system. *J. Control. Release* **2006**, *115*, 280–288. [[CrossRef](#)] [[PubMed](#)]
105. Blakney, A.K.; Ball, C.; Krogstad, E.A.; Woodrow, K.A. Electrospun fibers for vaginal anti-HIV drug delivery. *Antivir. Res.* **2013**, *100* (Suppl.), S9–S16. [[CrossRef](#)] [[PubMed](#)]
106. Caramella, C.M.; Rossi, S.; Ferrari, F.; Bonferoni, M.C.; Sandri, G. Mucoadhesive and thermogelling systems for vaginal drug delivery. *Adv. Drug Deliv. Rev.* **2015**, *92*, 39–52. [[CrossRef](#)] [[PubMed](#)]
107. Ensign, L.M.; Cone, R.; Hanes, J. Nanoparticle-based drug delivery to the vagina: A review. *J. Control. Release* **2014**, *190*, 500–514. [[CrossRef](#)] [[PubMed](#)]
108. Boyd, P.; Major, I.; Wang, W.; McConville, C. Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer. *Eur. J. Pharm. Biopharm.* **2014**, *88*, 945–953. [[CrossRef](#)] [[PubMed](#)]
109. Hu, X.; Liu, S.; Zhou, G.; Huang, Y.; Xie, Z.; Jing, X. Electrospinning of polymeric nanofibers for drug delivery applications. *J. Control. Release* **2014**, *185*, 12–21. [[CrossRef](#)] [[PubMed](#)]
110. Li, S.F.; Liu, D.X.; Zheng, Y.H.; Yue, Y.; Huang, Y.B.; Jing, X.B. Inhibitory effects of paclitaxel-loaded PLA nanofibers against mice cervical cancers. *Acta Polym. Sin.* **2012**, 1029–1034. [[CrossRef](#)]
111. Hani, U.; Shivakumar, H.G.; Anjum, H.; Pasha, M.Y. Preparation and optimization of curcumin-hydroxy propyl β cyclodextrin bioadhesive vaginal films for human papilloma virus-induced cervical cancer. *J. Biomater. Tissue Eng.* **2014**, *4*, 796–803. [[CrossRef](#)]
112. Bilensoy, E.; Çirpanlı, Y.; Şen, M.; Doğan, A.L.; Çalış, S. Thermosensitive mucoadhesive gel formulation loaded with 5-fu: Cyclodextrin complex for HPV-induced cervical cancer. *J. Incl. Phenom. Macrocycl. Chem.* **2007**, *57*, 363–370. [[CrossRef](#)]

113. Woolfson, A.D.; McCafferty, D.F.; McCarron, P.A.; Price, J.H. A bioadhesive patch cervical drug delivery system for the administration of 5-fluorouracil to cervical tissue. *J. Control. Release* **1995**, *35*, 49–58. [[CrossRef](#)]
114. McCarron, P.A.; Woolfson, A.D.; McCafferty, D.F.; Price, J.H.; Sidhu, H.; Hickey, G.I. Cytotoxicity of 5-fluorouracil released from a bioadhesive patch into uterine cervical tissue. *Int. J. Pharm.* **1997**, *151*, 69–74. [[CrossRef](#)]
115. Hodge, L.S.; Downs, L.S., Jr.; Chura, J.C.; Thomas, S.G.; Callery, P.S.; Soisson, A.P.; Kramer, P.; Wolfe, S.S.; Tracy, T.S. Localized delivery of chemotherapy to the cervix for radiosensitization. *Gynecol. Oncol.* **2012**, *127*, 121–125. [[CrossRef](#)] [[PubMed](#)]



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).